Cerus Corporation

CERS Healthcare Medical Devices

Revenue
+6.28%
EPS
−2,800.0%
Free cash flow
+2,471.3%
Total debt
−25.4%

Quarter to September 2026, against a year earlier

2.03 0.10 −4.69%
Market cap
$430.2M
P/E
0.0×
Fwd P/E
−65.1×
Dividend yield
—
F-score
5/9
Altman Z
−4.00
Beneish M
−2.87
Dividend safety
n/a
Older periods Dec '25 Mar '26 Jun '26 Sep '26
P/E ratio

+8 more quarters

0.00 0.00 0.00 0.00
P/S ratio
1.68 1.44 2.36 1.91
P/FCF ratio
354.35 0.00 0.00 971.53
P/Operating CF
63.33 (115.89) (220.09) 159.61
P/B ratio
6.04 5.17 8.28 6.29
EV/Sales
1.68 1.46 2.40 1.93
EV/EBITDA
0.00 0.00 9,004.57 0.00
EV/FCF
355.26 (293.71) (324.93) 984.16
Current Ratio
1.73 1.63 1.83 1.96
Net Debt/EBITDA
(4.07) 47.38 (6.19) 7.76
Debt/Equity
1.29 1.24 0.92 0.83
Earnings Yield
(3.89%) (2.75%) (1.20%) (1.59%)
Free Cash Flow Yield
0.28% (0.34%) (0.31%) 0.10%
Free Cash Flow per Share
0.03 (0.02) (0.02) 0.01
Book value per Share
0.34 0.35 0.35 0.38
Free Cash Flow
4.89 (3.28) (3.53) 2.42
EV/EBIT
0.00 0.00 0.00 0.00
Other line items

Show all line items

Columns are period end dates · fundamentals updated 6 Nov 2026